Skip to main navigation
Verve Therapeutics
  • About Us
  • Why Cardiovascular Disease
  • Our Approach
  • Our Pipeline
  • Culture & Careers
  • Investors
    • Overview
    • News & Events
    • Presentations
    • Stock Information
    • Corporate Governance
    • Financials & Filings
    • IR Resources

Presentations

Safety and Durability of VERVE-101
Targeted Delivery of Base Editors to Hepatocytes In Vivo

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2
Verve Therapeutics, Inc., all rights reserved
  • Contact Us
  • Privacy Policy
  • About Us
  • Why Cardiovascular Disease
  • Our Approach
  • Our Pipeline
  • Culture & Careers
  • Investors
    ►
      ◄ Back
    • Overview
    • News & Events
    • Presentations
    • Stock Information
    • Corporate Governance
    • Financials & Filings
    • IR Resources